Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

P. R. Hebert, J. M. Gaziano, K. S. Chan and C. H. Hennekens
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215-1204, USA.

OBJECTIVE: To examine whether cholesterol lowering with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin drugs) reduces the risks of stroke and total mortality. DATA SOURCES: We conducted a computerized literature search from 1985 through 1995 to identify all published trials testing statin drugs. The Cholesterol and Recurrent Events (CARE) data were added after the report was published in October 1996. Our search was limited to English-language articles and included published overviews containing relevant individual trials. TRIAL SELECTION: Criteria for inclusion of randomized trials in the overview were (1) statin drugs alone used to reduce lipid levels rather than multifactorial interventions including another type of cholesterol-lowering drug and (2) inclusion of data on deaths and/or strokes. DATA EXTRACTION: Data were extracted by 2 researchers, and only minor discrepancies, which were easily resolved by discussion, occurred. Principal investigators of the trials and their funding agencies were also contacted to secure any relevant data not included in the published reports. DATA SYNTHESIS: A total of 16 individual trials including approximately 29 000 subjects treated and followed up an average of 3.3 years were included in the overview. The average reductions in total and low-density lipoprotein cholesterol achieved were large-22% and 30%, respectively. A total of 454 strokes (fatal plus nonfatal) and 1175 deaths occurred. Those assigned to statin drugs experienced significant reductions in risks of stroke of 29% (95% confidence interval [CI], 14%-41%) as well as total mortality of 22% (95% CI, 12%-31%), which was attributable to a significant reduction in cardiovascular disease (CVD) deaths of 28% (95% CI, 16%-37%). There was no evidence of any increased risk in non-CVD mortality (relative risk [RR], 0.93; 95% CI, 0.75-1.14). There was also no significant increase in risk of cancer (RR, 1.03; 95% CI, 0.90-1.17). CONCLUSION: This overview of all published randomized trials of statin drugs demonstrates large reductions in cholesterol and clear evidence of benefit on stroke and total mortality. There was, as expected, a large and significant decrease in CVD mortality, but there was no significant evidence for any increases in either non-CVD deaths or cancer incidence.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A 70-Year-Old Man With a Transient Ischemic Attack: Review of Internal Carotid Artery Stenosis
Caplan
JAMA 2008;300:81-90.
ABSTRACT | FULL TEXT  

Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study
Agalliu et al.
Am J Epidemiol 2008;0:kwn141v1-kwn141.
ABSTRACT | FULL TEXT  

Review: Statins and stroke
Rodriguez-Yanez et al.
Therapeutic Advances in Cardiovascular Disease 2008;2:157-166.
ABSTRACT  

Reduction in Blood Pressure With Statins: Results From the UCSD Statin Study, a Randomized Trial
Golomb et al.
Arch Intern Med 2008;168:721-727.
ABSTRACT | FULL TEXT  

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
Strippoli et al.
BMJ 2008;336:645-651.
ABSTRACT | FULL TEXT  

Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort
Flick et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2218-2225.
ABSTRACT | FULL TEXT  

Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
Shachaf et al.
Blood 2007;110:2674-2684.
ABSTRACT | FULL TEXT  

Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI
Nieland et al.
J. Lipid Res. 2007;48:1832-1845.
ABSTRACT | FULL TEXT  

The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira and Weir
CJASN 2007;2:766-785.
ABSTRACT | FULL TEXT  

Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells
Sassano et al.
Cancer Res. 2007;67:4524-4532.
ABSTRACT | FULL TEXT  

Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans
Khurana et al.
Chest 2007;131:1282-1288.
ABSTRACT | FULL TEXT  

Does pravastatin promote cancer in elderly patients? A meta-analysis
Bonovas and Sitaras
CMAJ 2007;176:649-654.
ABSTRACT | FULL TEXT  

Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly
Setoguchi et al.
Circulation 2007;115:27-33.
ABSTRACT | FULL TEXT  

Statin Drugs and Risk of Advanced Prostate Cancer
Platz et al.
JNCI J Natl Cancer Inst 2006;98:1819-1825.
ABSTRACT | FULL TEXT  

Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
Bonovas et al.
JCO 2006;24:4808-4817.
ABSTRACT | FULL TEXT  

Statin and Cancer Risks: From Tasseomancy of Epidemiologic Studies to Meta-Analyses
Kim
JCO 2006;24:4796-4797.
FULL TEXT  

Breast Cancer Growth Prevention by Statins.
Campbell et al.
Cancer Res. 2006;66:8707-8714.
ABSTRACT | FULL TEXT  

American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively
Mcelduff et al.
Heart 2006;92:1213-1218.
ABSTRACT | FULL TEXT  

Statin Use and Risk of Lymphoid Neoplasms: Results from the European Case-Control Study EPILYMPH.
Fortuny et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:921-925.
ABSTRACT | FULL TEXT  

Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial
Howard et al.
JAMA 2006;295:655-666.
ABSTRACT | FULL TEXT  

Statins and Cancer Risk: A Meta-analysis
Dale et al.
JAMA 2006;295:74-80.
ABSTRACT | FULL TEXT  

Pretreatment with Simvastatin Reduces Lung Injury Related to Intestinal Ischemia-Reperfusion in Rats
Pirat et al.
Anesth. Analg. 2006;102:225-232.
ABSTRACT | FULL TEXT  

Outcomes in 45 Patients With Statin-Associated Myopathy
Hansen et al.
Arch Intern Med 2005;165:2671-2676.
ABSTRACT | FULL TEXT  

Can Statin Therapy Reduce the Risk of Breast Cancer?
Vogel
JCO 2005;23:8553-8555.
FULL TEXT  

Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies
Bonovas et al.
JCO 2005;23:8606-8612.
ABSTRACT | FULL TEXT  

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Prepared by: British Cardiac Society, British Hype
Heart 2005;91:v1-v52.
FULL TEXT  

Statins and Cancer -- Beyond the "One Drug, One Disease" Model
Hawk and Viner
NEJM 2005;352:2238-2239.
FULL TEXT  

Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis
Amarenco et al.
Stroke 2004;35:2902-2909.
ABSTRACT | FULL TEXT  

Terms and Conditions: Semantic Complexity and Aspirin Resistance
Hennekens et al.
Circulation 2004;110:1706-1708.
FULL TEXT  

Statin use after renal transplantation: a systematic quality review of trial-based evidence
Lentine and Brennan
Nephrol Dial Transplant 2004;19:2378-2386.
ABSTRACT | FULL TEXT  

Impact of Angiotensin-Converting Enzyme Inhibitors and Statins on Survival in Idiopathic Pulmonary Fibrosis
Nadrous et al.
Chest 2004;126:438-446.
ABSTRACT | FULL TEXT  

Usefulness of the American Academy of Pediatrics Recommendations for Identifying Youths With Hypercholesterolemia
O'Loughlin et al.
Pediatrics 2004;113:1723-1727.
ABSTRACT | FULL TEXT  

Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schonbeck and Libby
Circulation 2004;109:II-18-II-26.
ABSTRACT | FULL TEXT  

Hypothesis: Atorvastatin Has Pleiotropic Effects that Translate into Early Clinical Benefits on Cardiovascular Disease
Novela and Hennekens
J CARDIOVASC PHARMACOL THER 2004;9:61-63.
ABSTRACT  

Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry
Golomb et al.
Arch Intern Med 2004;164:153-162.
ABSTRACT | FULL TEXT  

Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses
Hennekens et al.
Arch Intern Med 2004;164:40-44.
ABSTRACT | FULL TEXT  

William M. Feinberg Lecture: Stroke Therapy in the Year 2025: Burden, Breakthroughs, and Barriers to Progress
Broderick
Stroke 2004;35:205-211.
ABSTRACT | FULL TEXT  

Cholesterol and the Risk of Ischemic Stroke
Bowman et al.
Stroke 2003;34:2930-2934.
ABSTRACT | FULL TEXT  

Lipid-Lowering Drugs and the Risk of Depression and Suicidal Behavior
Yang et al.
Arch Intern Med 2003;163:1926-1932.
ABSTRACT | FULL TEXT  

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
Law et al.
BMJ 2003;326:1423.
ABSTRACT | FULL TEXT  

Differential Effects of Lipid-Lowering Therapies on Stroke Prevention: A Meta-analysis of Randomized Trials
Corvol et al.
Arch Intern Med 2003;163:669-676.
ABSTRACT | FULL TEXT  

Plasma Lipid Profile and Incident Ischemic Stroke: The Atherosclerosis Risk in Communities (ARIC) Study
Shahar et al.
Stroke 2003;34:623-631.
ABSTRACT | FULL TEXT  

Trends in Treatment and Outcomes for Acute Stroke Patients in Ontario, 1992-1998
Tu and Gong
Arch Intern Med 2003;163:293-297.
ABSTRACT | FULL TEXT  

Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3
Majlesi et al.
J. Leukoc. Biol. 2003;73:107-117.
ABSTRACT | FULL TEXT  

The Statins as Anticancer Agents
Chan et al.
Clin. Cancer Res. 2003;9:10-19.
ABSTRACT | FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Statins and stroke: evidence for cholesterol-independent effects
Di Napoli et al.
Eur Heart J 2002;23:1908-1921.
 

Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol
Green et al.
QJM 2002;95:821-826.
ABSTRACT | FULL TEXT  

Transient Ischemic Attack
Johnston
NEJM 2002;347:1687-1692.
FULL TEXT  

The New National Cholesterol Education Program Guidelines: Clinical Challenges for More Widespread Therapy of Lipids to Treat and Prevent Coronary Heart Disease
Eidelman et al.
Arch Intern Med 2002;162:2033-2036.
FULL TEXT  

Treatment of Acute Ischemic Stroke: Part II: Neuroprotection and Medical Management
Broderick and Hacke
Circulation 2002;106:1736-1740.
FULL TEXT  

Cancer Prevention Science and Practice
Lippman and Hong
Cancer Res. 2002;62:5119-5125.
FULL TEXT  

Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol
Sukhova et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:1452-1458.
ABSTRACT | FULL TEXT  

Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study
Marshall and Rouse
BMJ 2002;325:197-197.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy for Prevention: More Evidence, More Pessimism
Petitti
JAMA 2002;288:99-101.
FULL TEXT  

Cholesterol Predicts Stroke Mortality in the Women's Pooling Project
Horenstein et al.
Stroke 2002;33:1863-1868.
ABSTRACT | FULL TEXT  

Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease
Gaspoz et al.
NEJM 2002;346:1800-1806.
ABSTRACT | FULL TEXT  

Use of Statins and Aspirin to Reduce Risks of Cardiovascular Disease
Hebert et al.
J CARDIOVASC PHARMACOL THER 2002;7:77-80.
 

Lipids and Pulmonary Function in the Third National Health and Nutrition Examination Survey
Cirillo et al.
Am J Epidemiol 2002;155:842-848.
ABSTRACT | FULL TEXT  

Statin-induced fibrotic nonspecific interstitial pneumonia
Lantuejoul et al.
Eur Respir J 2002;19:577-580.
ABSTRACT | FULL TEXT  

Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review
Gorelick
Stroke 2002;33:862-875.
ABSTRACT | FULL TEXT  

Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2002;87:423-437.
FULL TEXT  

Costs of aspirin and statins in general practice
Drummond et al.
QJM 2002;95:23-26.
ABSTRACT | FULL TEXT  

Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
Rizos and Mikhailidis
Cardiovasc Res 2001;52:199-207.
ABSTRACT | FULL TEXT  

Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions
Davidson
J CARDIOVASC PHARMACOL THER 2001;6:219-229.
ABSTRACT  

Lipid Disorders : Justification of Methods and Goals of Treatment
Braunstein et al.
Chest 2001;120:979-988.
ABSTRACT | FULL TEXT  

Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction
Amarenco
Neurology 2001;57:S35-44.
ABSTRACT | FULL TEXT  

Keynote address
Fieschi and Falcou
Neurology 2001;57:S82-86.
ABSTRACT | FULL TEXT  

Hormone Replacement in Women with a History of Breast Cancer
Pritchard
The Oncologist 2001;6:353-362.
ABSTRACT | FULL TEXT  

Ineffective Secondary Prevention in Survivors of Cardiovascular Events in the US Population: Report From the Third National Health and Nutrition Examination Survey
Qureshi et al.
Arch Intern Med 2001;161:1621-1628.
ABSTRACT | FULL TEXT  

Statins and Dementia
Golomb et al.
Arch Neurol 2001;58:1169-1170.
FULL TEXT  

Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol : The Veterans Affairs HDL Intervention Trial (VA-HIT)
Bloomfield Rubins et al.
Circulation 2001;103:2828-2833.
ABSTRACT | FULL TEXT  

High-Density Lipoprotein Cholesterol and Ischemic Stroke in the Elderly: The Northern Manhattan Stroke Study
Sacco et al.
JAMA 2001;285:2729-2735.
ABSTRACT | FULL TEXT  

Review: lipid lowering drugs decrease coronary artery disease (CAD) events but not all cause or CAD mortality in men with no history of CAD
Havranek
Evid. Based Med. 2001;6:85-85.
FULL TEXT  

Methods for the prediction of coronary heart disease risk
DURRINGTON and PRAIS
Heart 2001;85:489-490.
FULL TEXT  

Statin therapy - what now?
DTB 2001;39:17-21.
ABSTRACT | FULL TEXT  

Age and gender bias in statin trials
Bandyopadhyay et al.
QJM 2001;94:127-132.
ABSTRACT | FULL TEXT  

Treatment of Older Persons With Hypercholesterolemia With and Without Cardiovascular Disease
Aronow
J. Gerontol. A Biol. Sci. Med. Sci. 2001;56:138M-145.
ABSTRACT | FULL TEXT  

Prospective Study of Fat and Protein Intake and Risk of Intraparenchymal Hemorrhage in Women
Iso et al.
Circulation 2001;103:856-863.
ABSTRACT | FULL TEXT  

Reduction of Stroke Events With Pravastatin : The Prospective Pravastatin Pooling (PPP) Project
Byington et al.
Circulation 2001;103:387-392.
ABSTRACT | FULL TEXT  

Recent advances: Geriatric
BMJ 2001;322:86-89.
FULL TEXT  

Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association
Goldstein et al.
Circulation 2001;103:163-182.
FULL TEXT  

Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association
Goldstein et al.
Stroke 2001;32:280-299.
FULL TEXT  

Regular review: Prevention of ischaemic stroke
Gubitz and Sandercock
BMJ 2000;321:1455-1459.
FULL TEXT  

Clinical and research challenges in risk factors for cardiovascular diseases
Hennekens
Eur Heart J 2000;21:1917-1921.
 

Statins: underused by those who would benefit
Hulley et al.
BMJ 2000;321:971-972.
FULL TEXT  

Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
Pignone et al.
BMJ 2000;321:983-986.
ABSTRACT | FULL TEXT  

Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice Editorial Comment
Laufs et al.
Stroke 2000;31:2442-2449.
ABSTRACT | FULL TEXT  

Garlic for Treating Hypercholesterolemia: A Meta-Analysis of Randomized Clinical Trials
Stevinson et al.
ANN INTERN MED 2000;133:420-429.
ABSTRACT | FULL TEXT  

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study
Blais et al.
Arch Intern Med 2000;160:2363-2368.
ABSTRACT | FULL TEXT  

Pravastatin Therapy and the Risk of Stroke
White et al.
NEJM 2000;343:317-326.
ABSTRACT | FULL TEXT  

Opportunistic Discovery of Occult Disease by Use of Test Panels in New, Symptomatic Primary Care Outpatients: Yield and Cost of Case Finding
Takemura et al.
Clin. Chem. 2000;46:1091-1098.
ABSTRACT | FULL TEXT  

HDL-Cholesterol, Total Cholesterol, and the Risk of Stroke in Middle-Aged British Men
Wannamethee et al.
Stroke 2000;31:1882-1888.
ABSTRACT | FULL TEXT  

Serum lipids in young patients with ischaemic stroke: a case-control study
Albucher et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:29-33.
ABSTRACT | FULL TEXT  

Update on Antiplatelet Therapy for Stroke Prevention
Sacco and Elkind
Arch Intern Med 2000;160:1579-1582.
FULL TEXT  

Respiratory infection and coronary heart disease: progression of a paradigm
GRIMES et al.
QJM 2000;93:375-383.
ABSTRACT | FULL TEXT  

New Molecular Targets for Cholesterol-Lowering Therapy
Izzat et al.
J. Pharmacol. Exp. Ther. 2000;293:315-320.
ABSTRACT | FULL TEXT